Aims to target Alzheimers with unique vaccine

Alzinova AB is a Swedish biopharmaceutical company specializing in the treatment of Alzheimer’s disease - one of our major health scourges, without effective treatment options. The Company's proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that with high precision could target the toxic amyloid-β oligomers involved in the onset and progression of the disease.

Impact: A therapeutic vaccine as a long-acting and cost-effective drug for the treatment and prevention of Alzheimer's disease.

Stage: Phase 1 study in patients in Alzheimers patients

CEO: Kristina Torfgård
GUV Contact: Anders Waas